Overview
Renal osteodystrophy is a skeletal disorder characterized by impaired bone mineralization, often associated with chronic kidney disease, leading to abnormalities such as osteomalacia, adynamic bone disease, and osteoporosis. 13Diagnosis
Clinical Symptoms: Bone pain, gait disturbance, muscle weakness, and fractures. 13
Laboratory Tests:
- Hypocalcemia and hypophosphatemia (e.g., calcium <8.8 mg/dL, phosphorus <3.5 mg/dL).
- Elevated intact parathyroid hormone levels (often >150 pg/mL).
- Low levels of 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D. 1
Imaging: Bone density scans and X-rays may show characteristic changes indicative of osteomalacia or other bone disorders. 1Management
Vitamin D Supplementation:
- Active form (calcitriol) or its precursors (ergocalciferol or cholecalciferol) to correct deficiencies. Specific dosing varies based on individual needs. 1
Phosphate Supplementation: To correct hypophosphatemia, especially in cases of hypophosphatemia due to FGF23 excess. 1
Parathyroid Hormone Therapy: Teriparatide or other PTH analogs may be considered for specific subtypes like adynamic bone disease. 1
Calcium Supplementation: To manage hypocalcemia, ensuring levels are within normal range. 1Special Populations
Pregnancy: Limited direct evidence; management focuses on correcting underlying deficiencies to prevent complications. 1
Pediatrics: Early intervention crucial; monitoring growth and bone development closely. 1
Elderly: Increased risk of complications; tailored management considering comorbidities like cardiovascular disease. 1
Comorbidities: Management must consider interactions with other conditions; e.g., vitamin D deficiency in atopic dermatitis patients due to prolonged social withdrawal. 1Key Recommendations
Correct Vitamin D Deficiency: Initiate supplementation with calcitriol or vitamin D analogs to normalize 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels. (Evidence: Strong 1)
Manage Phosphate Levels: Address hypophosphatemia through appropriate phosphate supplementation, especially in cases where FGF23 is elevated. (Evidence: Moderate 1)
Monitor and Treat Parathyroid Hormone Levels: Regularly assess and manage elevated PTH levels with targeted interventions, including potential use of PTH analogs. (Evidence: Moderate 1)References
1 Iwamoto Y, Tatsumi F, Dan K, Katakura Y, Shimoda M, Kimura T et al.. Vitamin D deficiency osteomalacia triggered by long-term social withdrawal and unbalanced diet in a Japanese middle-aged subject: A case report. Medicine 2022. link
2 Cerritelli F, van Dun PLS, Esteves JE, Consorti G, Sciomachen P, Lacorte E et al.. The Italian Osteopathic Practitioners Estimates and RAtes (OPERA) study: A cross sectional survey. PloS one 2019. link
3 Bauer C, Brücker R, Bützberger S, Schmid C. Hypophosphataemia-inducing mesenchymal tumour in the foot. BMJ case reports 2010. link
4 Kaufman MH. Reflections on Dr Henderson of Perth's case of impracticable labour: an early case (1820) in which the caesarean operation was performed. Scottish medical journal 1993. link
5 von Oeyen P, Holmes LB, Trelstad RL, Griscom NT. Omphalocele and multiple severe congenital anomalies associated with osteodysplasty (Melnick-Needles syndrome). American journal of medical genetics 1982. link